Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MTPC, Novartis Revise Package Insert of Imusera/Gilenya in Response to Overseas Death
March 22, 2012
- MSD, BIKEN Sign Domestic Marketing Agreement for 3 Flu Vaccines
March 22, 2012
- Taiho Pharmaceutical Launches TS-1 in 4 Scandinavian Countries
March 22, 2012
- Acquisition by Lupin Improves Kyowa Pharmaceutical Industry’s Profitability: President Tsunoda
March 21, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 2
March 19, 2012
- Nichi-Iko Definitely to Enter as Global Top-10 Generics Company within 4 Years: President Tamura
March 16, 2012
- Fuji-Keizai Predicts Japan’s Generics Market to Exceed ¥580 Billion in 2014
March 16, 2012
- All-Case PMS for Sutent Lifted: Pfizer
March 16, 2012
- Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
- Teva-Kowa, Taiyo, Nippon Kayaku Apply for Approval of Gran Biosimilar
March 15, 2012
- Shionogi Submits Clinical Trial Application in Europe for OncoTherapy’s Cancer Vaccine
March 15, 2012
- Nichi-Iko Makes Yakuhan Its Subsidiary, Acquiring 69% of Company’s Stock
March 15, 2012
- Qol to Appoint Daiichi Sankyo Espha Chairman as Managing Director
March 15, 2012
- Nichi-Iko Announces New Med-Term Management Plan, Targets ¥130 Billion Sales in Mar 2016
March 15, 2012
- Baxter Reports Temporary Suspension in Shipments of Albumin Products to Japan
March 15, 2012
- MR Survey Shows Number of Doctors Visited, Detailing Activity Downtrend
March 14, 2012
- Pharmacists Rate Pfizer Highly for Generic Selection: Survey
March 14, 2012
- Nihon Chouzai to Provide Generic Drug Information System to Pharmacies of Other Companies
March 14, 2012
- Astellas and UMN Announce Favorable Phase II Results for Influenza HA Vaccine
March 14, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…